Mechanism of Action
IGF-1 LR3 acts as a potent agonist at IGF-1 receptors (IGF-1R) throughout the body, particularly in skeletal muscle, bone, and neural tissue.
IGF-1R Signaling (PI3K-Akt-mTOR Pathway)
IGF-1 LR3 binds IGF-1R with slightly lower affinity than native IGF-1 but far greater duration due to reduced IGFBP binding. Receptor activation triggers PI3K-Akt-mTOR signaling, driving protein synthesis, ribosome biogenesis, and anti-apoptotic signaling. mTORC1 activation is a central mediator of muscle protein synthesis.[1]Satellite Cell Activation and Muscle Hypertrophy
IGF-1 LR3 activates skeletal muscle satellite cells, the myogenic progenitor cells responsible for muscle fiber repair and new nuclei addition (essential for muscle hypertrophy). Satellite cell number and activity are rate-limiting for muscle growth beyond normal fiber size limits. IGF-1 signaling via calcineurin-NFAT pathway drives satellite cell differentiation and fusion into existing fibers.[2]Anti-catabolic and GH-Independent Anabolism
IGF-1 LR3 provides anabolic signaling independent of GH secretion, relevant for tissue repair, anti-aging, and recovery applications. It reduces glucocorticoid-driven catabolism by opposing cortisol's protein catabolic effects in muscle. This makes it useful in catabolic states (post-surgery, injury, aging-related muscle loss).[3]Research Overview
Muscle Hypertrophy and Protein Synthesis
Most StudiedIGF-1 LR3 is among the most potent anabolic agents in preclinical research. In rodent models, direct intramuscular injection produces localized hypertrophy (30-50% increase in fiber cross-sectional area). Systemic dosing increases lean body mass, muscle protein synthesis rates, and satellite cell activation markers.[2]
Recovery from Injury and Atrophy
Strong EvidenceIGF-1 LR3 accelerates recovery from muscle disuse atrophy, immobilization, and surgical injury. It prevents atrophy-associated satellite cell depletion and promotes faster return of functional muscle mass. Animal models of spinal cord injury show improved motor recovery with systemic IGF-1 LR3.[3]
Neural and Cognitive Effects
Moderate EvidenceIGF-1R is highly expressed in brain hippocampus and prefrontal cortex. IGF-1 LR3 crosses the blood-brain barrier and promotes neurogenesis, BDNF expression, and neuroprotection in rodent models. Studies in aging animals show cognitive preservation with chronic low-dose IGF-1 treatment.[1]
Calculate your IGF-1 LR3 dose Vial strength, BAC water, exact syringe draw in IU. Free, no signup. Open Calc →
Research Protocols
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Muscle recovery / repair | 50–100 µg | Once daily post-exercise | Subcutaneous or intramuscular |
| Anti-catabolic / injury | 20–50 µg | Once daily | Subcutaneous |
| Bilateral site injection | 50 µg per site | Post-workout, bilateral injection near target muscles | Intramuscular |
| Conservative start | 20–30 µg | Once daily | Subcutaneous |
Post-workout administration capitalizes on elevated blood flow and IGF-1R expression in recently exercised muscle. Some protocols use bilateral intramuscular injection near target muscles for localized hyperplasia signals, though evidence for site-specific hypertrophy advantage is mixed. 20-30 hour half-life means once-daily dosing provides sustained anabolic elevation.
Research protocols only. Not medical advice.
Peptide Interactions
Safety Profile
IGF-1 LR3 is a potent anabolic compound requiring careful use and monitoring.
WADA Status: Prohibited by WADA as an anabolic agent. Athletes subject to testing must not use this compound.
Hypoglycemia: The most significant acute risk. IGF-1 LR3 has ~8% binding affinity at insulin receptors. At doses above 100 mcg, hypoglycemia is possible, particularly in the fasted state. Always have fast-acting carbohydrates available.
Acromegaly-like effects: Chronic supraphysiological IGF-1 elevation can cause soft tissue and organ growth (jaw, hands, feet, heart). Effects are dose and duration dependent. Periodic IGF-1 level monitoring is essential for long-duration protocols.
Tumor risk: IGF-1 signaling promotes cell proliferation. Not recommended for anyone with a personal or family history of cancer. Theoretical risk is a primary safety concern for long-term use.
No FDA approval: Research compound. Not approved for any human use.
References
- [1]Clemmons DR. "Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer." Nat Rev Drug Discov. 2007;6(10):821-833.
- [2]Adams GR, McCue SA. "Localized infusion of IGF-I results in skeletal muscle hypertrophy in rats." J Appl Physiol. 1998;84(5):1716-1722.
- [3]Hameed M, et al. "Expression of IGF-I splice variants in young and old human skeletal muscle after high resistance exercise." J Physiol. 2003;547(Pt 1):247-254.